A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer

CONCLUSION: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.PMID:38576344 | DOI:10.3802/jgo.2024.35.e76

Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Hiromi Komazaki Kazuaki Takahashi Hiroshi Tanabe Yuichi Shoburu Misato Kamii Akina Tsuda Motoaki Saito Kyosuke Yamada Hirokuni Takano Hirofumi Michimae Aikou Okamoto Source Type: research